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Objectives: To collect health care resource utilization (HCRU) in the management 
of idiopathic pulmonary fibrosis (IPF) patients. MethOds: A retrospective, longi-
tudinal, cohort study design via chart review analysis of anonymized IPF patient 
records is being conducted in order to collect healthcare resource data from a major 
IPF treatment centre in Ontario, Canada. A convenience sample of 90 IPF patients 
was selected with inclusion criteria of adult age at diagnosis having a confirmed 
diagnosis of IPF, and minimum of one respirologist visit. Demographics and HCRU 
data were collected with descriptive statistics to be presented. Costs are presented 
in 2014 Canadian dollars. Results: For the preliminary analysis, 45 IPF patients 
met the study inclusion criteria. 30 were male with the mean age at diagnosis 
being 71.3 years (range 39-89 years). Information about IPF treatments, supportive 
medications, tests/procedures, physician visits and hospitalizations were obtained 
from the charts. The overall cost of the cohort was $873,936, with a mean cost per 
patient of $19,421 ($986-$117,004, ±$18,961). The 30 day cost per patient was $337. 
IPF treatments accounted for more than half the total cost ($494,416). Patients were 
stratified by disease severity at diagnosis and followed over progression. 33 were 
diagnosed as initially having mild disease, and 12 had moderate disease. Patients 
with mild disease were followed an average of 65.8 months and had an average 
per patient cost of $20,029 (30 day cost: $305). Moderate patients were followed 
an average of 35.0 months and had an average per patient cost of $17,747 (30 day 
cost: $592). cOnclusiOns: Preliminary results from a major IPF treatment centre 
indicate substantial HCRU associated with IPF management. The authors plan to 
complete data extraction at the centre in order to determine HCRU and cost results 
for the full cohort.
PRS34
CliniCal and EConomiC BuRdEn of aSthma and ChRoniC oBStRuCtivE 
PulmonaRy diSEaSE (CoPd) in Poland: EStimatEd imPaCt of PooR 
inhalation tEChniquE With inhalEd CoRtiCoStERoid and long-
aCting BEta agoniSt fixEd-doSE ComBinationS
Bijos P1, Kaczynski J1, Torvinen S2, Lenarczyk E3, Wrona W3, Plich A2, Lewis A4,  
Blackney M4
1Teva Pharmaceuticals Polska, Warszawa, Poland, 2Teva Pharmaceuticals Europe B.V., 
Amsterdam, The Netherlands, 3HealthQuest, Warszawa, Poland, 4Covance Market Access, London, 
UK
Objectives: Fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS) and 
long-acting beta agonists (LABA) are recommended in moderate to severe persis-
tent asthma and chronic obstructive pulmonary disease (COPD). The aim of the 
analysis was to evaluate the clinical and economic burden of asthma and COPD in 
Poland, and assess the impact of poor inhalation technique with ICS + LABA FDCs 
- which is common with inhalers - reimbursed in Poland on costs and resource 
use. MethOds: The eligible patient population was estimated based on Polish 
asthma and COPD prevalence rates, with the proportion of patients receiving FDCs 
based on available National Health Fund (NHF) data. Costs of inhalers, scheduled 
and unscheduled health care events were taken from publicly available sources. The 
analysis was conducted in one-year horizon from the payer and patient perspective 
(direct costs) and societal perspective (indirect costs). Frequency of poor inhalation 
technique (occurrence of critical inhaler errors) and the associated increased risk 
of unscheduled health care events were estimated based on a large (N = 1,664), 
cross-sectional, observational study, performed in Italy in 2008. Results: In Poland 
207,801 adults with asthma and COPD receive an ICS + LABA FDCs annually, of which 
56,937 are estimated to have poor inhalation technique. Total direct costs were 
estimated to be 378 million PLN (91.1 million EUR)and productivity loss costs – 20.4 
million PLN (4.9 million EUR) cOnclusiOns: The clinical and economic burden 
of asthma and COPD is considerable in Poland and poor inhalation technique is a 
substantial contributor to costs of unscheduled healthcare events. Novel inhalers 
with easier inhalation technique may offer clinical and economic benefits in the 
management of asthma and COPD.
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Objectives: To perform an analysis of the changes in the number and cost of hospi-
talizations of COPD patients after the introduction of the new inhalation medicines 
into the Positive drug list (PDL). MethOds: It is retrospective, real life observational 
study on the hospitalizations of COPD patients due to exacerbations and the inclusion 
of new medicinal products for the treatment of COPD in PDL for a 6-year period (2009-
2014). Data for the number of hospitalizations due to COPD exacerbations, their cost, 
and the number of COPD patients with valid health insurance status was collected 
from National Health Insurance Fund (NHIF). Newly entered medicinal products for 
COPD were extracted from the PDL. Macro-costing approach was applied to evalu-
ate the total medical costs on hospitalizations. Statistical processing was through 
Spearman and Pearson correlation, and Freedman test. Results: Before 2009 COPD 
pharmacotherapy was partially reimbursed by NHIF. ICS/LABA were included with 
100% reimbursement and LAMA with 75% in PDL in 2010. In 2013 and 2014 in PDL 
were included glycopyrronim, aclidinium and indacaterol/glycopyrronium with 75% 
reimbursement and two generic ICS/LABA with 100% reimbursement. A statistically 
significant decrease in the hospitalizations due to COPD exacerbations was observed 
– from 28% in 2009 to 19% in 2014 (p< 0.0001). On the other hand, there is an increase 
in the total cost of hospitalizations mostly due to the increase in the cost of hospital 
services. Statistically significant correlation with linear nature exists also between 
the number of hospitalizations and the number of health-insured patients with COPD. 
Increase in the number of health insured let to the increase in the hospitalizations 
resource utilization and cost to determine whether functional decline is associated 
with increased healthcare resource utilization and costs. MethOds: Medicare and 
commercial patients who received an endothelin-receptor antagonist (ERA), phospho-
diesterase type 5 inhibitor (PDE5) or prostacyclin (PG12) and reported a medical claim 
with an ICD-9-CM of 416.0, 416.8 or 416.9 or a medical claim indicating right heart 
catheterization (RHC) were identified from pharmacy and medical claims data from 
2009 through 2013. The date of initial therapy served as the index date. Using provider-
reported data from prior authorization forms required for prescribing advanced PAH 
therapies listed above, the WHO-FC was found for 437 patients (FCII= 99; FCIII= 282; 
FCIV= 56). Results: Linear models indicated that the FCIV cohort averaged signifi-
cantly more inpatient admissions (Ps< 0.001), longer lengths of stay (Ps< 0.01) and 
more ER visits (Ps< 0.01) than the FCII or FCIII cohorts. Costs analyses indicated that 
FCIV had significantly higher medical costs than FCII ($130,572/year vs $120,588/year) 
(P= 0.002) and significantly higher total costs (pharmacy + medical) ($180,828/year vs 
$162,072/year) (P= 0.004). cOnclusiOns: PAH patients demonstrated a high level of 
utilization and costs. Disease severity, indicated by WHO-FC, is associated with higher 
utilization and costs for FCIV patients. Only small differences were found between 
FCII and FCIII. The FCIII cohort was twice as large as the FCII cohort. This suggests 
difficulty differentiating between these two FCs and potential bias in the sampling 
when relying on the prior authorization form for this clinical information.
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Objectives: The Continuing to Confront COPD International Patient Survey 
estimated the prevalence and burden of chronic obstructive pulmonary disease 
(COPD) across 12 countries. The objective of this sub-study was to estimate the 
humanistic and economic burden associated with dyspnoea in Spanish patients 
with COPD. MethOds: Spanish COPD patients from a cross-sectional population-
based survey conducted between November 2012 and May 2013, including subjects 
> 40 years fulfilling a case-definition of COPD based on a self-reported physician 
diagnosis or symptomatology were included. Patients were further classified as no/
mild dyspnoea (mMRC < 2) and moderate/severe dyspnoea (mMRC > 2), according 
to modified Medical Council Scale (mMRC) score. Impact of dyspnoea on health-
related quality of life (QoL) measured with COPD Assessment Test (CAT) and costs 
were compared between the two groups. Direct healthcare costs included moderate 
(community treated) and severe COPD exacerbations (requiring emergency room 
visits and/or hospitalization), primary care visits, COPD treatment including oxygen 
use, and immunization in the previous 12 months. Indirect costs included work loss 
estimated using the Work Productivity and Activity Impairment Scale. Results: 303 
Spanish subjects were included; mean age 65.1 years old, 57% male and 73.6% self-
reported moderate to very severe COPD. 47.1% of the subjects included were classi-
fied as having moderate/severe dyspnoea. These dyspnoeic patients showed a higher 
impact on QoL (CAT score > 20): 57.2% vs 28.8%, as well as higher costs than patients 
reporting no/mild dyspnoea: direct costs: 3,938€ vs 1,818€ (p< 0.001), indirect costs: 
3,596€ vs 3,011€ (p= 0.426), societal costs: 7,534€ vs 4,828€ (p= 0.004). cOnclusiOns: 
The frequency of moderate/severe dyspnoea is high among Spanish COPD patients. 
Dysponea was associated with higher impact on QoL and higher societal costs. 
Healthcare strategies targeted to improve dyspnoea symptoms could reduce the 
burden associated with COPD.
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Objectives: The current project aims to (1) evaluate cost burden of smoking to Asia 
and (2) increase public awareness on smoking and its clinical and economic impact 
to the society. MethOds: This is a retrospective literature review aiming to inves-
tigate the published work related to the burden of smoking to smokers since 2000. 
All published articles related to cost of smoking were reviewed. The current costs 
of each pack of cigarettes in the target Asia-Pacific countries (Hong Kong, Malaysia, 
Thailand, Philippines, South Korea, Singapore and Australia) were documented. Both 
tobacco cost per smoker (out-of-pocket) and the direct health care cost per smoker 
were estimated. The prevalence of smokers in each country was documented and 
for the calculation of the out-of-pocket cost per each smoker based on published 
data. The direct health care expenditure was documented based on the published 
data. We also estimated the cost of saving if the smoker stops smoking accord-
ing to the specific age and the expected life expectancy in each country. All cost 
estimation was based on the year 2014. Results: In 2014, the estimated annual 
government expenditure on managing smoking related diseases was Hong Kong 
(USD 1.45 billion), Malaysia (USD 1.11 billion), Thailand (USD 8.48 billion), Philippines 
(USD 7.70 billion), South Korea (USD 1.61 billion), Singapore (USD 0.72 billion) and 
Australia (USD 1.69 billion). Among the 7 countries, the smokers spend the most 
in Australia, Singapore and Hong Kong. The annual out-of-pocket cost for smokers 
for one pack per day was Hong Kong (USD 2620), Malaysia (USD 1460), Thailand 
(USD 1095), Philippines (USD 511), South Korea (USD 1825), Singapore (USD 3650) 
and Australia (USD 6935). cOnclusiOns: The cost burden of smoking is high from 
both smokers and government perspectives. Reduction of the smoking population 
can significantly alleviate the disease burden and reduce public health expenditure.
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was based on the average monthly salary in the UK. A conservative assumption was 
made about the increased risk of a productive day being lost – associated with level 
of patient satisfaction to their treatment – by calculating an approximate number of 
unscheduled hospitalisations that users of a new inhaler would experience in the 
previous 12 months relative to Spiriva® HandiHaler®. Patient satisfaction with their 
inhaler was based on inhaler features that relate to ease of use and ergonomics and 
compared Spiriva® HandiHaler® to an improved inhaler. Results: The frequency 
of unscheduled hospitalisations for the new inhaler and Spiriva® HandiHaler® users 
were calculated at 0.34 and 0.38, resulting in 68 and 76 productive days lost annually, 
respectively. The total annual societal cost per patient was € 9,851 with the new inhaler 
and € 10,891 with Spiriva® HandiHaler®. The new inhaler costs € 1,040 less per annum 
than Spiriva® Handihaler®. cOnclusiOns: New inhalers with improved features 
have the potential to offer substantial societal cost savings in COPD compared with 
Spiriva® Handihaler®.
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Objectives: A real-life cost-effectiveness evaluation in 2008 showed that medica-
tion costs of budesonide/formoterol for maintenance and reliever therapy (MART) 
via dry powder inhaler (DPI) was significantly lower than medication costs associ-
ated with fixed-dose combination (FDC) of budesonide/formoterol in conventional 
way (FDC of ICS/LABA + additional reliever) and free adjustable combination (FAC) 
of budesonide and formoterol, with at least equal effectiveness. In 2014 the Dental 
and Pharmaceutical Benefits Agency (TLV) in Sweden assessed all inhaled corticos-
teroids (ICS), long-acting beta-2-agonists (LABA) and their FDCs where the outcomes 
suggested equal effectiveness across treatment strategies and a pricing corridor was 
implemented. The objective is to update the medication costs for a real-life cost-
effectiveness analysis of treating asthma in Swedish primary care and to evaluate 
the medication costs in Denmark. MethOds: Medication costs from 2006 included 
all pharmaceuticals in the analysis which were inflated to 2015 price levels and then 
compared to today’s actual prices of medications used in the FAC arm (Pulmicort® 
Turbuhaler® & Oxis® Turbuhaler®, plus terbutaline as needed), FDC arm (Bufomix® 
Easyhaler® plus terbutaline as needed) and the budesonide/formoterol MART arm 
(DuoResp® Spiromax®). The same analysis was conducted for both Sweden and 
Denmark. Results: The medication costs in the budesonide/formoterol MART arm 
is less costly when considering DuoResp® Spiromax®, SEK 3336.4 (SEK 4710.9) per 
patient and year compared to SEK 4163 (SEK 6157) in the FDC arm and SEK 7498.5 
(SEK 5637.6) FAC arm. In Denmark the same trend is visible where the MART arm 
was DK 4183.5 (DK 4573) compared to DK 4579 (DK 5905.2) in the conventional FDC 
arm and 4510.4 (DK 4511.7) in the FAC arm. cOnclusiOns: Compared to conven-
tional treatment arm (FDC + reliever) and free adjustable combination (FAC) arm, 
DuoResp® Spiromax® with MART usage has the potential to be cost saving option 
with at least equivalent efficacy.
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Objectives: This study aimed at estimating the cost-effectiveness of the fixed-dose 
combination indacaterol/glycopyrronium 85/43μ g (IND/GLY) against tiotropium 18μ g 
(TIO) and salmeterol/ fluticasone 50/500μ g (SFC) in the management of patients with 
COPD in Greece. MethOds: A microsimulation model was developed in MS Excel. 
Efficacy and utility data were obtained from the international literature (SHINE & 
ILLUMINATE studies) and mortality data from the WHO database. Distribution of 
patients by GOLD severity stage, maintenance costs and costs associated with severe/ 
non-severe exacerbations were taken from published Greek studies. Unit costs were 
taken from officially published sources (Price Bulletin, reimbursement list, DRGs). The 
study perspective was that of the Social Insurance Fund; costs and outcomes were 
discounted at 3.5%; outcomes are reported over time horizons of one, three, five and 
10 years and over a lifetime. Cost base year was 2014. Deterministic and probabilistic 
sensitivity analyses were conducted to test robustness of model results. Results: 
Treatment of COPD with IND/GLY is associated with increased efficacy both against 
SFC (additional life years [LYs]: 0.19; additional quality adjusted life-years [QALYs]: 
0.13) and TIO (additional LYs: 0.22; QALYs: 0.16). Although IND/GLY has a higher 
pharmaceutical cost (additional € 2,626 vs. SFC; additional € 2,679 vs. TIO), all other 
cost components (maintenance costs, severe and non-severe exacerbation costs) 
are reduced, resulting in a reduction of total costs by € 5,204 compared with SCF 
and € 7,126 compared with TIO. The sensitivity analyses confirmed that IND/GLY 
was dominant in the majority of iterations, with a probability of being cost effective 
at a threshold of € 30,000 per QALY gained of 99.9% and 97.1% versus SFC and TIO, 
respectively. cOnclusiOns: IND/GLY was found to be a dominant treatment strategy 
compared to SFC and TIO for the management of patients with COPD in Greece, which 
could lead to savings for the healthcare system.
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(r = 0.09 with Spearman and Pearson tests). cOnclusiOns: There is a decrease in 
the COPD hospitalizations after the introduction of the new inhaled medicines and 
increase in their cost due to increase in the cost of services.
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Objectives: Long-acting β 2-agonists (LABAs) and long-acting muscarinic antago-
nists (LAMAs) have shown efficacy in preventing exacerbations in patients with 
COPD. Though these agents are effective in the treatment of COPD, deterioration 
in the patient health status can persist and therefore there is a need for improved 
treatment outcomes. In the SPARK trial, dual bronchodilation with QVA149 demon-
strated advantages in reducing the risk of COPD exacerbations in severe and very 
severe patients when compared to single bronchodilation with tiotropium. The 
objective of the study was to stimate the clinical benefits and the budget impact 
associated with the use of indacaterol 110 μ g/glycopyrronium 50 μ g (QVA149) instead 
of tiotropium 18 μ , in severe and very severe COPD patients (GOLD C and D) in 
Portugal. MethOds: A cost-consequence model was developed using the SPARK 
study data to derive treatment outcomes associated to the use of QVA149 instead 
of tiotropium. Primary outcomes of interest were COPD exacerbations and direct 
cost for the NHS. Treatment outcomes and costs were estimated for a 1 year. Local 
data was used to identify the target population, resource use and overall treat-
ment costs. Results: It is estimated that there are 11,239 GOLD C and D patients 
treated with tiotropium. Assuming that 20.5% of COPD patients see their primary 
care doctor with complaints about symptoms and exacerbations 2,304 of those 
patients could be treated instead with QVA149. After 1 year of treatment with QVA 
149 it is estimated that patients will experience 1,291 fewer exacerbations with a 
reduction of € 136,544 in the overall treatment costs compared to treatment with 
tiotropium. cOnclusiOns: Symptom control in COPD is essential and evidence 
shows that dual bronchodilation with QVA149 brings benefits when compared to 
tiotropium. The use of QVA149 in symptomatic patients instead tiotropium may 
improve treatment outcomes and reduce overall costs for the Portuguese NHS.
PRS38
Can qva149 imPRovE ShoRt tERm outComES in PatiEntS With 
CoPd Without inCREaSing thE ovERall tREatmEnt CoStS foR thE 
PoRtuguESE nhS? oPtimizing tREatmEnt outComES With a RESPonSiBlE 
uSE of limitEd RESouRCES
Carrasco J1, Viriato D2, Cardoso I2
1Novartis Farma Portugal, Porto Salvo, Portugal, 2Novartis Farma – Produtos Farmacêuticos S.A., 
Porto Salvo, Portugal
Objectives: In the LANTERN study QVA149 significantly reduced the rate of mod-
erate or severe exacerbations by 31% (p= 0.048) over Salmeterol/Fluticasone (SFC). 
The evidence suggests that the use of QVA149 can optimize treatment outcomes 
in patients with mild-to-severe COPD but at what cost to the Portuguese NHS? 
The study objective was to quantify the potential clinical benefits and the budget 
impact associated with the use of QVA149 and SFC in the treatment of Portuguese 
patients with moderate-to-severe COPD with few or no exacerbations. MethOds: 
A cost-consequence model was developed using the LANTERN study data to derive 
treatment outcomes for QVA149 and SFC. Primary outcomes of interest were COPD 
exacerbations (total, moderate and severe) and direct cost for the Portuguese NHS. 
Treatment outcomes and costs were estimated for 1 year time horizon. Local data 
was used to identify the target population, resource uses and overall treatment 
costs. Results: It is estimated that there are 73,739 GOLD B patients diagnosed 
and treated in Portugal and 34,778 of those patients are treated with SFC and could 
be eligible to receive treatment with QVA149. After one year of treatment with SFC 
it is estimated that these patients may experience 30,605 exacerbations (15,650 
moderate/severe) with a total treatment cost of € 69,268,710. If treated with QVA149 
it is estimated that these patients may experience 6,608 fewer exacerbations (4,869 
fewer moderate/severe) with a total treatment cost saving of € 8,524,307 versus SFC 
treatment. cOnclusiOns: The analysis suggest that once a day QVA149 can pro-
vide better treatment outcomes in patients with COPD with fewer treatment costs 
for the Portuguese NHS when compared with twice a day SFC in the treatment of 
moderate-to-severe COPD with few or no exacerbations.
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Objectives: Spiriva® Handihaler® (tiotropium) is available in a single capsule 
dry powder inhaler (DPI) for the treatment of COPD. As exacerbations and hospi-
talisations represent an important driver of the cost and morbidity of COPD, high 
priority should be given to interventions aimed at delaying the progression of dis-
ease, preventing exacerbations, and reducing the risk of comorbidities to alleviate 
the clinical and economic burden of disease. The potential societal cost benefits of 
improving treatment satisfaction, due to improved characteristics of an inhaler were 
investigated. MethOds: The eligible adult patient population was based on con-
firmed COPD diagnoses in UK, with the proportion of patients receiving Spiriva® 
Handihaler® based on market research data. The annual number of work days lost 
due to COPD was based on data from the UK. The monetary value of a productive day 
